Observational studyEuropean journal of pediatrics2025
Changes in the anthropometric measurements in children and adolescents with coeliac disease over a two-year follow-up.
Observational study in European journal of pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to evaluate changes in anthropometric measurements in paediatric coeliac disease (CD) patients following the initiation of a gluten-free diet (GFD), and to identify baseline characteristics associated with growth recovery. An observational study with retrospective data collection of medical records was conducted on paediatric CD patients (2-18 years) diagnosed between 2010 and 2020. Diagnosis of CD was established based on the ESPGHAN criteria with and without biopsy. Anthropometric measurements were converted to age- and sex-specific z-scores. Data were collected at diagnosis (T0) and at two time points: T1 (5.5-9 months post-diagnosis) and T2 (17-25 months post-diagnosis). Univariate generalised linear models and DAG-informed regression models were used for statistical analysis. The study included 439 CD patients (66% female). At diagnosis, mean z-scores for weight-for-age (WAZ) and height-for-age (HAZ) were significantly lower than reference values. Significant increases in WAZ, HAZ and BMI-for-age z-score (BMIZ) were observed from baseline (T0) to T2. Younger age at diagnosis was associated with greater increases in WAZ and HAZ. Children with typical symptoms showed greater growth recovery in WAZ and BMIZ compared to those with atypical symptoms. TTG-IgA levels at T2 were not associated with growth outcomes.
conclusionChildren with CD exhibit significant catch-up growth after starting a GFD, with early and sustained improvements in weight and height. Younger age at diagnosis and typical presentation predict greater growth recovery, underscoring the importance of early detection and treatment. WHAT IS KNOWN: • Growth impairment is a common manifestation in children with undiagnosed CD. • Changes in the degree of growth recovery in relation to patients' clinical and biochemical profiles are not fully elucidated. WHAT IS NEW: • Paediatric CD patients demonstrate significant height recovery, with mean height z-scores approaching the population average of zero. • Younger age at diagnosis and more severe symptoms are associated with greater growth recovery.
Indexed as
Identifiers
41125955What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.